Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of 131I-BIBH 1 in Presurgical NSCLC
NCT02199886Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1998
- Primary completion
- Dec 2001
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of sibrotuzumab in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of dose-limiting toxicities at 30 days, Number of patients with abnormal biodistribution for 131I BIBH 1 at 30 days and 1 more. Started Jul 1998; status: terminated.
02
Drugs
sibrotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02199886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199886.